Page last updated: 2024-11-08

epothilone b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID448013
CHEMBL ID94657
CHEBI ID31550
CHEBI ID94639
SCHEMBL ID3808
MeSH IDM0247231

Synonyms (74)

Synonym
epo 906a
epithilone b
CHEMBL94657
chebi:31550 ,
gnf-pf-193 ,
epo-906a
patupilone [inn]
uec0h0urse ,
epo906
unii-uec0h0urse
HY-17029
epo-906
(-)-epothilone b
(-)-epothilone b, from sorangium cellulosum, >=98% (hplc)
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione
4,17-dioxabicyclo(1410)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1s,3s,7s,10r,11s,12s,16r)-
epo 906
4,17-dioxabicyclo(1410)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1s-(1r*,3r*(e),7r*,10s*,11r*,12r*,16s*))-
NCGC00181131-01
7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-thiazol-4-yl)vinyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
epothilone b ,
patupilone
152044-54-7
epo b
DB03010
nsc-684363
epothilon b
nsc684363
epothilone b, synthetic
epob
LMPK04000041
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(e)-1-(2-methyl-4-thiazolyl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
(1s,3s,7s,10r,11s,12s,16r)-8,8,10,12,16-pentamethyl-3-[(e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-7,11-bis(oxidanyl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
A809247
tox21_112738
dtxcid60819918
cas-152044-54-7
dtxsid4046862 ,
epothilone-b
AKOS015951072
BCPP000100
150322-43-3 pound not389574-19-0
CS-0714
S1364
4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((1e)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl)-, (1s,3s,7s,10r,11s,12s,16r)-
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)vinyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione
patupilone [who-dd]
epo906a
patupilone [mart.]
epothilone b [mi]
BRD-K48935217-001-01-3
SCHEMBL3808
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((e)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
AC-22614
patupilonum
patupilona
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
mfcd02101921
bdbm50103627
EX-A1244
epothilone b(patupilone)
epothilone b (epo906, patupilone)
CHEBI:94639
(1s,3s,7s,10r,11s,12s,16r)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(e)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
patupilone (epothilone b)
F17412
patupilone (epo906, epothilone b)
QXRSDHAAWVKZLJ-PVYNADRNSA-N
Q27093987
CCG-269760
NCGC00181131-04
E1378

Research Excerpts

Overview

Epothilone B (EpoB) is a potent antitumor natural product with sub-nanomolar anti-proliferation action against several human cancer cells. It is a non-taxane microtubule-stabilizing agent with a mode of action similar to that of paclitaxel, but with the advantage of being active in pac litaxel-resistant cells.

ExcerptReferenceRelevance
"Epothilone B (EpoB) is an FDA-approved anti-neoplastic agent used to treat metastatic breast cancer; However, its usage is limited due to its severe peripheral neurotoxicity. "( Epothilone B inactivation of Sirtuin1 promotes mitochondrial reactive oxygen species to induce dysfunction and ferroptosis of Schwann cells.
Lei, T; Li, K; Liang, Z; Wang, X; Zhang, J; Zhang, N, 2023
)
3.8
"Epothilone B (Epo B) is a potent antitumor natural product with sub-nanomolar anti-proliferation action against several human cancer cells. "( Tumor selective self-assembled nanomicelles of carbohydrate-epothilone B conjugate for targeted chemotherapy.
Fang, M; Ge, X; Liu, Y; Liu, ZP; Lou, H; Qian, L; Xu, Y; Xu, ZJ; Zhang, Z, 2023
)
2.6
"Epothilone B is a natural product that stabilizes microtubules, similar to paclitaxel (Taxol); therefore, epothilone B and several derivatives have shown obvious antitumour activities. "( Heterologous redox partners supporting the efficient catalysis of epothilone B biosynthesis by EpoK in Schlegelella brevitalea.
Bian, X; Ding, X; Liang, J; Wang, H; Zhang, Y; Zhao, G, 2020
)
2.24
"Epothilone B (EpoB) is a non-taxane microtubule-stabilizing agent with a mode of action similar to that of paclitaxel, but with the advantage of being active in paclitaxel-resistant cells. "( Tumor necrosis factor-alpha related gene response to Epothilone B in ovarian cancer.
Arango, D; Augenlicht, LH; Goldberg, GL; Gross, SJ; Khabele, D; Lopez-Jones, M; Yang, W, 2004
)
2.02
"Epothilone B (BMS-247550) is a semisynthetic analog of the natural product epothilone B."( Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
Dawkins, F; Erlichman, C; Ettinger, DS; Fitch, T; Fracasso, PM; Kraut, M; Mahoney, MR; Maples, WJ; Okuno, S; Stewart, J, 2005
)
1.41
"Epothilone B is a 16-membered macrolide produced by the myxobacterium Sorangium cellulosum and is currently under clinical investigation. "( In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.
Aichholz, R; Blum, W; Brüggen, J; Flörsheimer, A; Kühnöl, J; O'Reilly, T; Ramstein, P, 2001
)
2.07

Effects

Epothilone B has drawn great attention due to its much stronger anticancer activity and weaker side effects compared with taxol. Aza-epothilones B has been advanced to phase I clinical trials by the Bristol-Myers Squibb group.

ExcerptReferenceRelevance
"Epothilone B has drawn great attention due to its much stronger anticancer activity and weaker side effects compared with taxol. "( A new approach for improving epothilone B yield in Sorangium cellulosum by the introduction of vgb epoF genes.
Chen, Y; Li, H; Li, S; Liu, T; Pan, Q; Tan, G; Ye, W; Zhang, W, 2016
)
2.17
"Aza-epothilone B has been advanced to phase I clinical trials by the Bristol-Myers Squibb group."( On the interactivity of complex synthesis and tumor pharmacology in the drug discovery process: total synthesis and comparative in vivo evaluations of the 15-aza epothilones.
Bornmann, WG; Chappell, MD; Chou, TC; Danishefsky, SJ; Guan, Y; Lee, CB; Spassova, M; Stachel, SJ, 2001
)
0.79

Treatment

Epothilone B treatment decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. Treatment with epothilones B and D at different concentrations (1-100 nmol/L) dose-dependently inhibited cell growth and caused cell cycle arrest.

ExcerptReferenceRelevance
"Epothilone B treatment at doses of 10-6 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. "( Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.
Anthony, CT; Balster, DA; Frey, DJ; Harrison, LH; Lewis, JM; Maxwell, PJ; O'Leary, JP; Rothermel, J; Wang, YZ; Woltering, EA, 2003
)
1.76
"Treatment with epothilone B and D at different concentrations (1-100 nmol/L) dose-dependently inhibited cell growth and caused cell cycle arrest at G2-M, which was followed by apoptosis."( Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway.
Hong, JT; Kim, SM; Kim, TJ; Lee, HW; Lee, SH; Moon, DC; Ryu, JC; Son, DJ; Son, SM; Song, S; Yoon, DY, 2007
)
0.68

Toxicity

ExcerptReferenceRelevance
" Adverse events, dose-limiting toxicities (DLT), MTD, and tumor response were determined."( Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Hirte, HW; Johri, AR; Kaye, S; Oza, AM; Smit, WM; Spanik, S; Sufliarsky, J; Ten Bokkel Huinink, WW; Wagnerova, M, 2009
)
0.35
" In this study, we investigated the epothilone B toxic effect in vitro and we characterized in vivo the general and neurological side effects of epothilone B administration in Wistar and Fischer rats."( Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies.
Bianchi, R; Canta, A; Cavaletti, G; Cervellini, I; Chiorazzi, A; Cossa, G; Crippa, D; Lauria, G; Lombardi, R; Melcangi, RC; Nicolini, G; Oggioni, N; Rigolio, R; Roglio, I, 2009
)
1

Pharmacokinetics

ExcerptReferenceRelevance
" The mean pharmacokinetic parameter values during course 1 for clearance, volume of distribution, and apparent terminal elimination half-life at the 40 mg/m(2) (recommended Phase II dose) dose level were 21 liters/h/m(2), 826 liters/m(2), and 35 h (excluding one outlier of 516 h), respectively."( Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
Cohen, MB; Griffin, T; Hamilton, A; Hochster, H; Horwitz, SB; Khabelle, D; Lebwohl, DE; Liebes, L; Mani, S; McDaid, H; Muggia, F, 2004
)
0.55
" The simulated human pharmacokinetic profiles from the PBPK model showed good agreement with observed clinical pharmacokinetic data, where the model predicted AUC, t(1/2), V(ss), and CL values were within approximately twofold of the observed values for all dose groups."( Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
He, H; Heimbach, T; Lin, TH; Tan, E; Wang, Y; Xia, B, 2012
)
0.38
"A simple LC-MS/MS method was developed for determination and pharmacokinetic study of Epothilone B in rat plasma."( LC-MS/MS method for determination of epothilone B in rat plasma and its application in pharmacokinetic study.
Lu, HM; Ye, M, 2012
)
0.88

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present phase Ib study examined the safety/tolerability and pharmacokinetics of patupilone in combination with carboplatin in patients with advanced solid tumors."( A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Cheung, W; Forster, M; Gore, M; Johri, A; Kaye, S; Oza, A; Sklenar, I; Zaknoen, S, 2007
)
0.34
"Chemotherapy regimens including gemcitabine in combination with microtubule inhibitors such as docetaxel and paclitaxel have wide clinical application."( A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Alberti, D; Bailey, H; Brandon, H; Eickhoff, J; Holen, K; Morgan-Meadows, S; Oliver, K; Schelman, W; Thomas, JP; Wilding, G, 2008
)
0.35
"The aim was to determine the potential of the allosteric mammalian target of rapamycin inhibitor, everolimus, to act in combination with cytotoxic anticancer compounds in vitro and in vivo."( Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Further research is required to determine optimal dosing strategies and to fully assess the compound's activity against other malignant diseases."( Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
Cabral, F; Finlay, V; Logothetis, CJ; Navone, NM; Newman, RA; Nicolaou, KC; Raymond, M; Stephens, LC; Troncoso, P; Vourloumis, D; Wu, X; Yang, J, 2001
)
0.6
" Two phase I studies with EPO906 were conducted to determine the safety and maximal tolerated dose on two different dosing schedules: weekly and every 3 weeks."( EPO906 (epothilone B): a promising novel microtubule stabilizer.
Chen, T; Hohneker, J; Rothermel, J; Wartmann, M, 2003
)
0.75
" At higher doses, DLTs were observed using both dosing schedules, with diarrhea the most common DLT."( Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Chen, T; Ho, YY; Hsu, CH; Hubert, M; Oza, AM; Rothermel, J; Rubin, EH; Tesfaye, F, 2005
)
0.33
" Metronomic dosing regimes use lower drug doses and prolonged drug exposure times in an attempt to decrease toxicity compared with standard dosing schedules."( Metronomic dosing enhances the anti-angiogenic effect of epothilone B.
Anthony, CT; Stalder, MW; Woltering, EA, 2011
)
0.61
"Epothilone B, when dosed by a metronomic schedule may have a significant anti-angiogenic effect on human solid tumors."( Metronomic dosing enhances the anti-angiogenic effect of epothilone B.
Anthony, CT; Stalder, MW; Woltering, EA, 2011
)
2.06
" Dose modification including dose reduction and dosing schedule modification may be utilized to manage toxicities, but this must be based on careful hematologic, neurologic, and liver function monitoring."( Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton, N, 2010
)
0.36
" MPD provided constant plasma levels, whereas IVBD had very high C0/Cmin ratios of 70-280 (rat) or 8000 (mouse) over the dosing cycle."( Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
Becquet, M; Gschwind, HP; Laborde, L; McSheehy, PM; O'Reilly, TM; Pfaar, U; Sterker, D; Texier, C; Wartmann, M, 2018
)
0.48
" In particular, the 10 nM EpoB dosage was shown to increase the axon elongation, cell alignment, and upregulation of these MN-markers compared with other doses."( Microtubule stabilizer epothilone B as a motor neuron differentiation agent for human endometrial stem cells.
Ai, J; Basiri, A; Ebrahimi-Barough, S; Hasanzadeh, E; Hassannejad, Z; Mahmoodi, N; Rahimi-Movaghar, V; Vaccaro, AR, 2020
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
microtubule-stabilising agentAny substance that interacts with tubulin to promote polymerisation of microtubules.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
epothiloneAny member of the class of 16-membered macrolide natural products, or their analogues, normally containing a double bond or its epoxide at positions 12-13 and bearing hydroxy groups at positions 4 and 8, methyl groups at positions 5, 5, 7, and 9, an oxo group at position 6, and a 1-(2-substituted-1,3-thiazol-4-yl)prop-1-en-2-yl substituent at position 15.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.01470.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency0.00130.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency0.01820.000221.22318,912.5098AID743035; AID743063
pregnane X nuclear receptorHomo sapiens (human)Potency7.94330.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.43720.000229.305416,493.5996AID743075; AID743091
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency10.00000.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.01510.000323.4451159.6830AID743065; AID743067
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency3.34980.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.03430.005612.367736.1254AID624032; AID624044
Interferon betaHomo sapiens (human)Potency0.01470.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.01710.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-4A chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin beta chainHomo sapiens (human)IC50 (µMol)0.00350.00052.052910.0000AID1408257
Tubulin alpha-3C chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin alpha-1B chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin alpha-4A chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin beta-4B chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin beta-3 chainHomo sapiens (human)IC50 (µMol)0.00350.00051.894510.0000AID1408257
Tubulin beta-2A chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin beta-8 chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin alpha-3E chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin alpha-1A chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin alpha-1C chainHomo sapiens (human)IC50 (µMol)0.00350.00051.955510.0000AID1408257
Tubulin beta-6 chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin beta-2B chainHomo sapiens (human)IC50 (µMol)0.00350.00051.968010.0000AID1408257
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)0.00350.00051.987010.0000AID1408257
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)22.10000.00203.519610.0000AID1215086; AID1215094
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)0.01000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (210)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of microtubule polymerizationTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4A chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
odontoblast differentiationTubulin beta chainHomo sapiens (human)
microtubule-based processTubulin beta chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin beta chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta chainHomo sapiens (human)
regulation of synapse organizationTubulin beta chainHomo sapiens (human)
spindle assemblyTubulin beta chainHomo sapiens (human)
cell divisionTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta chainHomo sapiens (human)
mitotic cell cycleTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1B chainHomo sapiens (human)
microtubule-based processTubulin alpha-1B chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1B chainHomo sapiens (human)
cell divisionTubulin alpha-1B chainHomo sapiens (human)
cellular response to interleukin-4Tubulin alpha-1B chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-4A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-4A chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta-4B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-3 chainHomo sapiens (human)
axon guidanceTubulin beta-3 chainHomo sapiens (human)
netrin-activated signaling pathwayTubulin beta-3 chainHomo sapiens (human)
dorsal root ganglion developmentTubulin beta-3 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-3 chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2A chainHomo sapiens (human)
oocyte maturationTubulin beta-8 chainHomo sapiens (human)
spindle assembly involved in female meiosisTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-8 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-8 chainHomo sapiens (human)
biological_processTubulin alpha-3E chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3E chainHomo sapiens (human)
neuron migrationTubulin alpha-1A chainHomo sapiens (human)
startle responseTubulin alpha-1A chainHomo sapiens (human)
intracellular protein transportTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1A chainHomo sapiens (human)
centrosome cycleTubulin alpha-1A chainHomo sapiens (human)
smoothened signaling pathwayTubulin alpha-1A chainHomo sapiens (human)
memoryTubulin alpha-1A chainHomo sapiens (human)
adult locomotory behaviorTubulin alpha-1A chainHomo sapiens (human)
visual learningTubulin alpha-1A chainHomo sapiens (human)
response to mechanical stimulusTubulin alpha-1A chainHomo sapiens (human)
glial cell differentiationTubulin alpha-1A chainHomo sapiens (human)
gene expressionTubulin alpha-1A chainHomo sapiens (human)
dentate gyrus developmentTubulin alpha-1A chainHomo sapiens (human)
cerebellar cortex morphogenesisTubulin alpha-1A chainHomo sapiens (human)
pyramidal neuron differentiationTubulin alpha-1A chainHomo sapiens (human)
cerebral cortex developmentTubulin alpha-1A chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1A chainHomo sapiens (human)
response to tumor necrosis factorTubulin alpha-1A chainHomo sapiens (human)
locomotory exploration behaviorTubulin alpha-1A chainHomo sapiens (human)
microtubule polymerizationTubulin alpha-1A chainHomo sapiens (human)
forebrain morphogenesisTubulin alpha-1A chainHomo sapiens (human)
homeostasis of number of cells within a tissueTubulin alpha-1A chainHomo sapiens (human)
regulation of synapse organizationTubulin alpha-1A chainHomo sapiens (human)
synapse organizationTubulin alpha-1A chainHomo sapiens (human)
cell divisionTubulin alpha-1A chainHomo sapiens (human)
neuron apoptotic processTubulin alpha-1A chainHomo sapiens (human)
motor behaviorTubulin alpha-1A chainHomo sapiens (human)
cellular response to calcium ionTubulin alpha-1A chainHomo sapiens (human)
organelle transport along microtubuleTubulin alpha-1A chainHomo sapiens (human)
neuron projection arborizationTubulin alpha-1A chainHomo sapiens (human)
response to L-glutamateTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1C chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1C chainHomo sapiens (human)
cell divisionTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-6 chainHomo sapiens (human)
neuron migrationTubulin beta-2B chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2B chainHomo sapiens (human)
modulation of chemical synaptic transmissionTubulin beta-2B chainHomo sapiens (human)
positive regulation of axon guidanceTubulin beta-2B chainHomo sapiens (human)
embryonic brain developmentTubulin beta-2B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2B chainHomo sapiens (human)
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (59)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
GTPase activityTubulin beta-4A chainHomo sapiens (human)
calcium ion bindingTubulin beta-4A chainHomo sapiens (human)
protein bindingTubulin beta-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4A chainHomo sapiens (human)
GTP bindingTubulin beta-4A chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
GTPase activityTubulin beta chainHomo sapiens (human)
structural molecule activityTubulin beta chainHomo sapiens (human)
protein bindingTubulin beta chainHomo sapiens (human)
protein domain specific bindingTubulin beta chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin beta chainHomo sapiens (human)
GTPase activating protein bindingTubulin beta chainHomo sapiens (human)
MHC class I protein bindingTubulin beta chainHomo sapiens (human)
protein-containing complex bindingTubulin beta chainHomo sapiens (human)
metal ion bindingTubulin beta chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta chainHomo sapiens (human)
GTP bindingTubulin beta chainHomo sapiens (human)
hydrolase activityTubulin alpha-3C chainHomo sapiens (human)
metal ion bindingTubulin alpha-3C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
GTP bindingTubulin alpha-3C chainHomo sapiens (human)
double-stranded RNA bindingTubulin alpha-1B chainHomo sapiens (human)
GTPase activityTubulin alpha-1B chainHomo sapiens (human)
structural molecule activityTubulin alpha-1B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-1B chainHomo sapiens (human)
GTP bindingTubulin alpha-1B chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-4A chainHomo sapiens (human)
hydrolase activityTubulin alpha-4A chainHomo sapiens (human)
protein kinase bindingTubulin alpha-4A chainHomo sapiens (human)
metal ion bindingTubulin alpha-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
GTP bindingTubulin alpha-4A chainHomo sapiens (human)
double-stranded RNA bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-4B chainHomo sapiens (human)
protein bindingTubulin beta-4B chainHomo sapiens (human)
MHC class I protein bindingTubulin beta-4B chainHomo sapiens (human)
metal ion bindingTubulin beta-4B chainHomo sapiens (human)
unfolded protein bindingTubulin beta-4B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4B chainHomo sapiens (human)
GTP bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-3 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-3 chainHomo sapiens (human)
protein bindingTubulin beta-3 chainHomo sapiens (human)
GTP bindingTubulin beta-3 chainHomo sapiens (human)
peptide bindingTubulin beta-3 chainHomo sapiens (human)
metal ion bindingTubulin beta-3 chainHomo sapiens (human)
netrin receptor bindingTubulin beta-3 chainHomo sapiens (human)
GTPase activityTubulin beta-2A chainHomo sapiens (human)
protein bindingTubulin beta-2A chainHomo sapiens (human)
metal ion bindingTubulin beta-2A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2A chainHomo sapiens (human)
GTP bindingTubulin beta-2A chainHomo sapiens (human)
molecular_functionTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-8 chainHomo sapiens (human)
metal ion bindingTubulin beta-8 chainHomo sapiens (human)
GTP bindingTubulin beta-8 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-8 chainHomo sapiens (human)
molecular_functionTubulin alpha-3E chainHomo sapiens (human)
protein bindingTubulin alpha-3E chainHomo sapiens (human)
hydrolase activityTubulin alpha-3E chainHomo sapiens (human)
metal ion bindingTubulin alpha-3E chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
GTP bindingTubulin alpha-3E chainHomo sapiens (human)
structural molecule activityTubulin alpha-1A chainHomo sapiens (human)
protein bindingTubulin alpha-1A chainHomo sapiens (human)
hydrolase activityTubulin alpha-1A chainHomo sapiens (human)
identical protein bindingTubulin alpha-1A chainHomo sapiens (human)
protein-containing complex bindingTubulin alpha-1A chainHomo sapiens (human)
metal ion bindingTubulin alpha-1A chainHomo sapiens (human)
protein heterodimerization activityTubulin alpha-1A chainHomo sapiens (human)
GTP bindingTubulin alpha-1A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
structural molecule activityTubulin alpha-1C chainHomo sapiens (human)
protein bindingTubulin alpha-1C chainHomo sapiens (human)
hydrolase activityTubulin alpha-1C chainHomo sapiens (human)
metal ion bindingTubulin alpha-1C chainHomo sapiens (human)
GTP bindingTubulin alpha-1C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
molecular_functionTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-6 chainHomo sapiens (human)
protein bindingTubulin beta-6 chainHomo sapiens (human)
metal ion bindingTubulin beta-6 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-6 chainHomo sapiens (human)
GTP bindingTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainHomo sapiens (human)
protein bindingTubulin beta-2B chainHomo sapiens (human)
metal ion bindingTubulin beta-2B chainHomo sapiens (human)
protein heterodimerization activityTubulin beta-2B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2B chainHomo sapiens (human)
GTP bindingTubulin beta-2B chainHomo sapiens (human)
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (53)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusTubulin beta-4A chainHomo sapiens (human)
cytosolTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
axonemeTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4A chainHomo sapiens (human)
internode region of axonTubulin beta-4A chainHomo sapiens (human)
neuronal cell bodyTubulin beta-4A chainHomo sapiens (human)
myelin sheathTubulin beta-4A chainHomo sapiens (human)
intercellular bridgeTubulin beta-4A chainHomo sapiens (human)
extracellular exosomeTubulin beta-4A chainHomo sapiens (human)
mitotic spindleTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
cytoplasmTubulin beta-4A chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionTubulin beta chainHomo sapiens (human)
nucleusTubulin beta chainHomo sapiens (human)
nuclear envelope lumenTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
cytosolTubulin beta chainHomo sapiens (human)
cytoskeletonTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta chainHomo sapiens (human)
azurophil granule lumenTubulin beta chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin beta chainHomo sapiens (human)
cell bodyTubulin beta chainHomo sapiens (human)
membrane raftTubulin beta chainHomo sapiens (human)
intercellular bridgeTubulin beta chainHomo sapiens (human)
extracellular exosomeTubulin beta chainHomo sapiens (human)
mitotic spindleTubulin beta chainHomo sapiens (human)
protein-containing complexTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
nucleusTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
microtubuleTubulin alpha-3C chainHomo sapiens (human)
cytoplasmTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmTubulin alpha-1B chainHomo sapiens (human)
extracellular regionTubulin alpha-4A chainHomo sapiens (human)
cytosolTubulin alpha-4A chainHomo sapiens (human)
cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-4A chainHomo sapiens (human)
cytoplasmTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
extracellular regionTubulin beta-4B chainHomo sapiens (human)
nucleusTubulin beta-4B chainHomo sapiens (human)
cytosolTubulin beta-4B chainHomo sapiens (human)
cytoskeletonTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
axonemal microtubuleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4B chainHomo sapiens (human)
azurophil granule lumenTubulin beta-4B chainHomo sapiens (human)
intercellular bridgeTubulin beta-4B chainHomo sapiens (human)
extracellular exosomeTubulin beta-4B chainHomo sapiens (human)
mitotic spindleTubulin beta-4B chainHomo sapiens (human)
extracellular vesicleTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
cytoplasmTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
lamellipodiumTubulin beta-3 chainHomo sapiens (human)
filopodiumTubulin beta-3 chainHomo sapiens (human)
axonTubulin beta-3 chainHomo sapiens (human)
dendriteTubulin beta-3 chainHomo sapiens (human)
growth coneTubulin beta-3 chainHomo sapiens (human)
neuronal cell bodyTubulin beta-3 chainHomo sapiens (human)
intercellular bridgeTubulin beta-3 chainHomo sapiens (human)
extracellular exosomeTubulin beta-3 chainHomo sapiens (human)
cell peripheryTubulin beta-3 chainHomo sapiens (human)
mitotic spindleTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
cytoplasmTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2A chainHomo sapiens (human)
intercellular bridgeTubulin beta-2A chainHomo sapiens (human)
extracellular exosomeTubulin beta-2A chainHomo sapiens (human)
mitotic spindleTubulin beta-2A chainHomo sapiens (human)
extracellular vesicleTubulin beta-2A chainHomo sapiens (human)
cytoplasmTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-8 chainHomo sapiens (human)
intercellular bridgeTubulin beta-8 chainHomo sapiens (human)
extracellular exosomeTubulin beta-8 chainHomo sapiens (human)
mitotic spindleTubulin beta-8 chainHomo sapiens (human)
meiotic spindleTubulin beta-8 chainHomo sapiens (human)
microtubuleTubulin beta-8 chainHomo sapiens (human)
cytoplasmTubulin beta-8 chainHomo sapiens (human)
nucleusTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
microtubuleTubulin alpha-3E chainHomo sapiens (human)
cytoplasmTubulin alpha-3E chainHomo sapiens (human)
condensed chromosomeTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1A chainHomo sapiens (human)
cytosolTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
axonemal microtubuleTubulin alpha-1A chainHomo sapiens (human)
plasma membraneTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
neuromuscular junctionTubulin alpha-1A chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin alpha-1A chainHomo sapiens (human)
recycling endosomeTubulin alpha-1A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
cytoplasmTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
vesicleTubulin alpha-1C chainHomo sapiens (human)
membrane raftTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmTubulin alpha-1C chainHomo sapiens (human)
nucleusTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-6 chainHomo sapiens (human)
intercellular bridgeTubulin beta-6 chainHomo sapiens (human)
extracellular exosomeTubulin beta-6 chainHomo sapiens (human)
mitotic spindleTubulin beta-6 chainHomo sapiens (human)
cytoplasmTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
nucleusTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainHomo sapiens (human)
intercellular bridgeTubulin beta-2B chainHomo sapiens (human)
mitotic spindleTubulin beta-2B chainHomo sapiens (human)
Schaffer collateral - CA1 synapseTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (126)

Assay IDTitleYearJournalArticle
AID1525185Cytotoxicity against human PC3 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID506685Displacement of [3H]discodermolide from microtubule assessed as bound radioligand level at 20 uM treated before radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID1454528Growth inhibition of human A549 cells after 4 days by SRB assay2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Synthesis and Evaluation of a Linkable Functional Group-Equipped Analogue of the Epothilones.
AID1525186Cytotoxicity against human A549 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID662232Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1408253Cytotoxicity against human HeLa cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1408252Cytotoxicity against human KBV1 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID662231Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID256549Inhibitory concentration against beta-tubulin mutant 1A9PTX22 cell line2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID1616892Cytotoxicity against mouse L929 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID94006Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID1525093Cytotoxicity in mouse L929 cells2019Journal of natural products, 05-24, Volume: 82, Issue:5
Sesquiterpenes from an Eastern African Medicinal Mushroom Belonging to the Genus Sanghuangporus.
AID1490886Cytotoxicity against human A549 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1866157Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID662238Cell cycle arrest in human SNU398 cells assessed as accumulation at G1 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 55.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1616894Cytotoxicity against human KB3-1 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID662217Antiproliferative activity against human SNU398 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662234Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1422678Antiproliferative activity against human MCF7 cells after 2 days by MTT assay2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B.
AID662220Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1616918Cytotoxicity against human SKOV3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID1454527Growth inhibition of human PC3 cells after 4 days by SRB assay2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Synthesis and Evaluation of a Linkable Functional Group-Equipped Analogue of the Epothilones.
AID1404410Cytotoxicity against human KB 3.1 cells assessed as inhibition of cell growth after 5 days by MTT assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microporenic Acids A-G, Biofilm Inhibitors, and Antimicrobial Agents from the Basidiomycete Microporus Species.
AID1525094Cytotoxicity in human KB 3.1 cells2019Journal of natural products, 05-24, Volume: 82, Issue:5
Sesquiterpenes from an Eastern African Medicinal Mushroom Belonging to the Genus Sanghuangporus.
AID1490884Cytotoxicity against human KB3-1 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID159417Concentrations required to induce 50 percent polymerization of porcine brain-derived micro-tubule protein2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID1408254Cytotoxicity against human Hs 578T cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1866160Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1616916Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID1408256Inhibition of GFP-tagged alpha-tubulin (unknown origin) expressed in human MCF7 cells assessed as disruption of microtubule polymerization2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1408261Antiproliferative activity against human 8226/LR-5 cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID662219Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID599626Induction of microtubule assembly by photoaffinity labeling study2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Total synthesis and evaluation of 22-(3-azidobenzoyloxy)methyl epothilone C for photoaffinity labeling of beta-tubulin.
AID1408250Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID662224Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662240Cell cycle arrest in human SNU398 cells assessed as accumulation at sub-G1 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 1.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1454745Cytotoxicity against human 1A9 cells2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1433226Cytotoxicity against HUVEC after 5 days by MTT assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.
AID1408258Antiproliferative activity against human RPM18226 cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1672882Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization.
AID1525184Cytotoxicity against human MCF7 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID1616893Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID599629Cytotoxicity against human NCI/ADR cells by phototoxicity labeling study2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Total synthesis and evaluation of 22-(3-azidobenzoyloxy)methyl epothilone C for photoaffinity labeling of beta-tubulin.
AID356712Cytotoxicity against mouse L929 cells2001Journal of natural products, Jul, Volume: 64, Issue:7
New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies.
AID662239Cell cycle arrest in human SNU398 cells assessed as accumulation at G2 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 38.2%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1525187Cytotoxicity against human SKOV3 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID1616917Cytotoxicity against human PC3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID367974Displacement of non-fluorescent ligand from paclitaxel binding site of microtubule2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological activities of high affinity taxane-based fluorescent probes.
AID255449Percent polymorphism of tubulin by the compound2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID662223Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662226Antiproliferative activity against human JHH4 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID506688Displacement of [3H]paclitaxel from microtubule assessed as bound radioligand level at 20 uM treated after radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID506675Binding affinity to microtubule2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID506687Displacement of [3H]epothilone B from microtubule assessed as bound radioligand level at 20 uM treated before radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID662229Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID255844Inhibitory concentration against beta-tubulin mutant 1A9PTX22 cell line2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID1675242Cytotoxicity against human KB3.1 cells assessed as reduction in cell viability by MTT assay2020Journal of natural products, 08-28, Volume: 83, Issue:8
Heimiomycins A-C and Calamenens from the African Basidiomycete
AID1490890Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1490883Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1408251Cytotoxicity against human KB3-1 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID662221Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1525183Cytotoxicity against human KB3-1 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID1195238Antiproliferative activity against exponentially growing adherent human SCC114 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID1195236Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID662245Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G2 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 26.1%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1675241Cytotoxicity against mouse L929 cells assessed as reduction in cell viability by MTT assay2020Journal of natural products, 08-28, Volume: 83, Issue:8
Heimiomycins A-C and Calamenens from the African Basidiomycete
AID1195237Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation at 10 uM after 72 hrs by luminescence detection based ATPlite assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
AID1404411Cytotoxicity against mouse L929 cells assessed as inhibition of cell growth after 5 days by MTT assay2018Journal of natural products, 04-27, Volume: 81, Issue:4
Microporenic Acids A-G, Biofilm Inhibitors, and Antimicrobial Agents from the Basidiomycete Microporus Species.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID506689Displacement of [3H]paclitaxel from microtubule assessed as bound radioligand level at 20 uM treated before radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID1525182Cytotoxicity against mouse L929 cells measured after 5 days by MTT assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Kenalactams A-E, Polyene Macrolactams Isolated from Nocardiopsis CG3.
AID662218Antiproliferative activity against human PLC/PRF/5 cells2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1490887Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1866159Cytotoxicity against human A-431 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID662246Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at sub-G1 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 1.4%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID506686Displacement of [3H]epothilone B from microtubule assessed as bound radioligand level at 20 uM treated after radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID1408257Inhibition of tubulin polymerization in human MCF7 cells assessed as induction of mitotic arrest2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID662228Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1866158Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID662244Cell cycle arrest in human PLC/PRF/5 cells assessed as accumulation at G1 phase at 100 nM after 24 hrs by FACS analysis (Rvb = 66.8%)2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1490889Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1408260Antiproliferative activity against human MM1S cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1714657Induction of oligomerization calf brain tubulin assessed as formation of microtubule at 100 uM incubated for 30 mins in presence of GTP and 3 mM Mg2+ by electron micrography analysis2018Journal of natural products, 03-23, Volume: 81, Issue:3
Zampanolide Binding to Tubulin Indicates Cross-Talk of Taxane Site with Colchicine and Nucleotide Sites.
AID1672883Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization.
AID255823Inhibitory concentration against ovarian carcinoma 1A9 cell growth2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID1866155Cytotoxicity against human KB 3-1 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID94043Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID1490885Cytotoxicity against human A431 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1215092Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 up to 46 uM after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1408262Antiproliferative activity against human RPMI8226/MR20 cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1422677Antiproliferative activity against human MCF7 cells at 0.01 to 100 nmol/L after 2 days by MTT assay2018Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B.
AID1616919Cytotoxicity against human A431 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
AID506684Displacement of [3H]discodermolide from microtubule assessed as bound radioligand level at 20 uM treated after radioligand addition by competitive binding assay2007Nature chemical biology, Feb, Volume: 3, Issue:2
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
AID1490888Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 5 days by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Preussilides A-F, Bicyclic Polyketides from the Endophytic Fungus Preussia similis with Antiproliferative Activity.
AID1866154Cytotoxicity against mouse L929 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID662225Antiproliferative activity against human JHH2 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1866156Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
AID1408259Antiproliferative activity against human U266 cells assessed as inhibition of cell proliferation2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID1408255Inhibition of paclitaxel binding to microtubule (unknown origin)2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis and antitumor activity of epothilone B.
AID662227Antiproliferative activity against human JHH7 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID255856Inhibitory concentration against beta-tubulin mutant 1A9PTX10 cell growth2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID662233Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID159565Induction of polymerization of porcine brain-derived microtubule protein by 2 uM epothilone B2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and biological evaluation of highly potent analogues of epothilones B and D.
AID256550Inhibitory concentration against beta-tubulin mutant 1A9PTX10 cell growth2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID94562Cytotoxicity against L929 fibroblast cell line; Weak cytotoxic activity.1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Derivatization of the C12-C13 functional groups of epothilones A, B and C.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID599628Cytotoxicity against human MCF7 cells by phototoxicity labeling study2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Total synthesis and evaluation of 22-(3-azidobenzoyloxy)methyl epothilone C for photoaffinity labeling of beta-tubulin.
AID1433227Cytotoxicity against human KB 3.1 cells after 5 days by MTT assay2016Journal of natural products, 06-24, Volume: 79, Issue:6
Pyristriatins A and B: Pyridino-Cyathane Antibiotics from the Basidiomycete Cyathus cf. striatus.
AID662222Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID662230Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (300)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (4.33)18.2507
2000's142 (47.33)29.6817
2010's123 (41.00)24.3611
2020's22 (7.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.27 (24.57)
Research Supply Index5.81 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index61.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (8.85%)5.53%
Reviews33 (10.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other245 (80.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (53)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone(BMS-247550) and Carboplatin in Patients With HER2/Neu-Positive Metastatic Breast Cancer [NCT00077376]Phase 261 participants (Actual)Interventional2005-03-31Completed
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas [NCT00045708]Phase 1/Phase 257 participants (Actual)Interventional2002-10-31Completed
A Phase II Evaluation of Epothilone-B BMS 247550 (NSC # 710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer [NCT00025155]Phase 251 participants (Actual)Interventional2002-07-31Completed
A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma [NCT00095979]Phase 252 participants (Actual)Interventional2005-05-31Completed
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IV [NCT00977574]Phase 2349 participants (Actual)Interventional2009-09-14Active, not recruiting
A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer [NCT00411528]Phase 2185 participants (Actual)Interventional2006-09-30Completed
A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or [NCT00262990]Phase 3829 participants (Actual)Interventional2005-11-30Completed
A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer [NCT00877500]Phase 2116 participants (Anticipated)Interventional2009-03-30Active, not recruiting
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial. [NCT00715013]Phase 1/Phase 29 participants (Actual)Interventional2008-07-31Completed
Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer [NCT01084057]Phase 156 participants (Actual)Interventional2010-05-17Completed
A Phase I Study of Epothilone B Analog BMS 247550 in Combination With Carboplatin in Recurrent and/or Refractory Solid Tumors [NCT00028561]Phase 145 participants (Actual)Interventional2001-10-31Terminated(stopped due to Administratively complete.)
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer [NCT00785291]Phase 3799 participants (Actual)Interventional2008-10-13Completed
EPO906 Phase I 6-arm Trial to Optimize Administration Exploring Single Dose Bolus and Continuous Infusion Over 1 or 5 Days Every 3 or 4 Weeks in Patients With Pretreated Advanced Colon Cancer With Nutritional Support Treatment and Intensive Management of [NCT00969046]Phase 160 participants (Actual)Interventional2003-11-30Completed
A Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients [NCT00884676]Phase 136 participants (Actual)Interventional2008-11-30Completed
Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer [NCT00450866]Phase 255 participants (Actual)Interventional2007-01-31Completed
Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy [NCT00331344]Phase 1/Phase 2100 participants (Actual)Interventional2006-04-30Completed
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer [NCT00035243]Phase 253 participants (Actual)Interventional2002-04-30Completed
An Open Label, Phase I/II Dose Escalating Study Evaluating the Safety and Efficacy of EPO906, qw3, in Patients With Non-small Cell Lung Cancer. [NCT00171834]Phase 1/Phase 289 participants (Actual)Interventional2003-08-31Completed
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus [NCT01168232]Phase 242 participants (Actual)Interventional2010-09-07Completed
Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors [NCT00331643]Phase 2120 participants (Actual)Interventional2006-04-30Completed
Phase II Study of a Weekly Schedule of BMS-247550 for Patients With Hormone Refractory Prostate Cancer [NCT00087139]Phase 2124 participants (Actual)Interventional2004-09-30Completed
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignan [NCT00426140]Phase 15 participants (Actual)Interventional2006-08-31Completed
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer [NCT00328458]Phase 139 participants (Actual)Interventional2004-02-29Completed
An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension) [NCT00442741]Phase 10 participants (Actual)Interventional2007-07-31Withdrawn(stopped due to pts. will be captured in core)
An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies [NCT00448396]Phase 117 participants (Actual)Interventional2007-03-31Completed
Phase I Study of Patupilone and RAD001 in Patients With Refractory Solid Tumor Malignancy [NCT00496600]Phase 142 participants (Actual)Interventional2007-07-31Completed
A Phase II Trial of BMS 247550 (Ixabepilone) in Advanced Renal Cell Carcinoma [NCT00182702]Phase 237 participants (Actual)Interventional2005-07-31Completed
An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function [NCT00420524]Phase 136 participants (Actual)Interventional2006-01-31Completed
An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies-extension Study [NCT00468260]Phase 112 participants (Anticipated)Interventional2007-05-31Terminated(stopped due to pts. will be captured in core)
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer [NCT00035113]Phase 248 participants (Actual)Interventional2002-01-31Completed
A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer [NCT00058084]Phase 280 participants (Actual)Interventional2003-03-31Completed
A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium [NCT00021099]Phase 245 participants (Actual)Interventional2001-06-30Completed
A Phase II Study of Epothilone B Analog (BMS-247550) in Advanced Soft Tissue Sarcomas [NCT00022542]Phase 226 participants (Actual)Interventional2001-06-30Terminated
A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer [NCT00023946]Phase 250 participants (Actual)Interventional2001-08-31Terminated
A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck [NCT00033618]Phase 2144 participants (Actual)Interventional2002-11-30Completed
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer [NCT00035100]Phase 254 participants (Actual)Interventional2001-09-30Completed
EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors [NCT00050349]Phase 233 participants (Actual)Interventional2002-07-31Completed
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer [NCT00035087]Phase 262 participants (Actual)Interventional2002-05-31Completed
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer [NCT00035126]Phase 246 participants (Actual)Interventional2002-01-31Completed
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Melanoma [NCT00035165]Phase 251 participants (Actual)Interventional2002-03-31Completed
A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma [NCT00036764]Phase 288 participants (Actual)Interventional2002-02-28Completed
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10) [NCT00159484]Phase 1/Phase 275 participants (Actual)Interventional2004-10-31Active, not recruiting
A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer [NCT00407251]Phase 273 participants (Anticipated)Interventional2007-02-28Completed
A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors [NCT00412789]Phase 115 participants (Actual)Interventional2006-08-31Completed
An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC) [NCT00273312]Phase 225 participants (Actual)Interventional2006-01-31Completed
An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies [NCT00420615]Phase 134 participants (Actual)Interventional2006-12-31Completed
An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function [NCT00421044]Phase 114 participants (Actual)Interventional2006-05-31Completed
A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane [NCT00182767]Phase 1/Phase 245 participants (Actual)Interventional2006-01-31Completed
A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas [NCT00058019]Phase 251 participants (Actual)Interventional2003-02-28Completed
A Phase 2 Study of Trastuzumab in Combination With BMS-247550 in Women With Metastatic Breast Cancer [NCT00079326]Phase 239 participants (Actual)Interventional2004-01-31Terminated(stopped due to Slow accrual.)
A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors [NCT00426582]Phase 148 participants (Actual)Interventional2006-08-31Completed
Phase I Study of Ixabepilone and Temsirolimus in Adult Patients With Advanced Solid Tumors [NCT01375829]Phase 122 participants (Actual)Interventional2011-06-27Active, not recruiting
An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer. [NCT00219297]Phase 250 participants (Actual)Interventional2005-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00025155 (4) [back to overview]Overall Survival
NCT00025155 (4) [back to overview]Progression Free Survival
NCT00025155 (4) [back to overview]Tumor Response
NCT00025155 (4) [back to overview]Number of People With Adverse Effects
NCT00045708 (10) [back to overview]Duration of Overall Survival
NCT00045708 (10) [back to overview]Measure Pharmacokinetic Parameters Using Clearance as Related to BMS-247550 and Anticonvulsant Measurements
NCT00045708 (10) [back to overview]Grade 3 and 4 Toxicity (NCI Common Terminology Criteria for Adverse Events Associated With BMS-247550 Treatment in at Least 5% of Patients
NCT00045708 (10) [back to overview]Group A (P450) Estimated MTD and Group B (nonP450) Estimated MTD of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma
NCT00045708 (10) [back to overview]Measure Pharmacokinetic Parameters Using Estimation of Half-lives Related to BMS-247550 and Anticonvulsants
NCT00045708 (10) [back to overview]Measure Pharmacokinetic Parameters Using Volume of Distribution at Steady State as Related to BMS-247550 and Anticonvulsants
NCT00045708 (10) [back to overview]Percent of Subjects With 6M Progression Free Survival at the Phase 2 Arm of Study
NCT00045708 (10) [back to overview]Response Rate of Patients at the MTD
NCT00045708 (10) [back to overview]The Duration of Progression Free Survival (Phase 2)
NCT00045708 (10) [back to overview]Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma
NCT00058019 (5) [back to overview]Duration of Response
NCT00058019 (5) [back to overview]Objective Overall Response Rate
NCT00058019 (5) [back to overview]Overall Survival
NCT00058019 (5) [back to overview]Safety and Toxicity of Ixabepilone
NCT00058019 (5) [back to overview]Time to Progression
NCT00077376 (8) [back to overview]Kaplan-Meier Estimate of Overall Survival at 3 Years for HER2+ Patients
NCT00077376 (8) [back to overview]Time to Disease Progression for All Treated Patients
NCT00077376 (8) [back to overview]Time to Disease Progression for HER2+ Patients
NCT00077376 (8) [back to overview]Time to Treatment Failure for All Treated Patients
NCT00077376 (8) [back to overview]Objective Response for All Treated Patients (the Best Response a Patient Has Ever Experienced on Study)
NCT00077376 (8) [back to overview]Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study)
NCT00077376 (8) [back to overview]Time to Treatment Failure for HER2+ Patients
NCT00077376 (8) [back to overview]Kaplan-Meier Estimate of Overall Survival at 3 Years for All Treated Patients
NCT00079326 (2) [back to overview]Time to Treatment Failure (TTF)
NCT00079326 (2) [back to overview]Overall Response Rate
NCT00087139 (4) [back to overview]Duration of Measurable Disease Response
NCT00087139 (4) [back to overview]Duration of PSA Response
NCT00087139 (4) [back to overview]Proportion of Patients With Measurable Disease Response (Best Overall Response)
NCT00087139 (4) [back to overview]Proportion of Patients With PSA Response
NCT00095979 (4) [back to overview]Tumor Response
NCT00095979 (4) [back to overview]Overall Survival
NCT00095979 (4) [back to overview]Frequency and Severity of Observed Adverse Effects Associated With Protocol Therapy (CTCAE Version 3)
NCT00095979 (4) [back to overview]Progression-free Survival
NCT00171834 (8) [back to overview]Number of Participants With Best Overall Response-Phase I
NCT00171834 (8) [back to overview]Time to Progression (TTP)-Phase I and Phase II
NCT00171834 (8) [back to overview]Time to Overall Response -Phase I and Phase II
NCT00171834 (8) [back to overview]Overall Survival Time-Phase I and Phase II
NCT00171834 (8) [back to overview]Duration of Stable Disease-Phase I and Phase II
NCT00171834 (8) [back to overview]Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00171834 (8) [back to overview]Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)
NCT00171834 (8) [back to overview]Duration of Overall Response -Phase I and Phase II
NCT00182767 (4) [back to overview]Maximum Tolerated Dose
NCT00182767 (4) [back to overview]Proportion of Patients Responding to Therapy (Complete Response [CR], Partial Response [PR], or Stable Disease [SD]), Assessed According to Response Evaluation Criteria in Solid Tumors (RECIST) and Cancer Antigen-125 (CA-125) Response Criteria (Phase II)
NCT00182767 (4) [back to overview]Progression-free Survival
NCT00182767 (4) [back to overview]Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I)
NCT00331344 (4) [back to overview]Time to Progression (Phase II)
NCT00331344 (4) [back to overview]Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).
NCT00331344 (4) [back to overview]Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)
NCT00331344 (4) [back to overview]Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)
NCT00450866 (5) [back to overview]Overall Survival
NCT00450866 (5) [back to overview]Toxicity as Measured by NCI CTCAE v3.0
NCT00450866 (5) [back to overview]CNS Response Rate, for Measurable Disease Will be Assessed by the Modified McDonald Criteria
NCT00450866 (5) [back to overview]Systemic Disease Response Rate for Measurable Disease Will be Assessed by the Modified McDonald Criteria
NCT00450866 (5) [back to overview]Central Nervous System (CNS) Progression-free Survival(PFS)
NCT00785291 (5) [back to overview]Time to Treatment Failure
NCT00785291 (5) [back to overview]Progression Free Survival
NCT00785291 (5) [back to overview]Overall Survival
NCT00785291 (5) [back to overview]Objective Tumor Response Rate
NCT00785291 (5) [back to overview]12 Month Progression Free Survival
NCT00977574 (4) [back to overview]Frequency and Severity of Toxicity as Assessed by CTCAE v3.0 for Each of the Three Arms.
NCT00977574 (4) [back to overview]The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
NCT00977574 (4) [back to overview]Number of Participants Who Progressed or Died by 25 Months From Enrollment
NCT00977574 (4) [back to overview]The Median Duration of Overall Survival for Each of the Three Arms.
NCT01168232 (4) [back to overview]Objective Tumor Response
NCT01168232 (4) [back to overview]Overall Survival
NCT01168232 (4) [back to overview]Adverse Events (Grade 3 or Higher) During Treatment Period.
NCT01168232 (4) [back to overview]Progression-free Survival

Overall Survival

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT00025155)
Timeframe: From study entry to death or last contact, up to 5 years of follow-up.

InterventionMonths (Median)
Treatment (Ixabepilone)14.8

[back to top]

Progression Free Survival

"Progression-Free Survival is the period from study entry until disease progression, death or date of last contact, whichever occurs first.~Progression is defined as at least a 20% increase in the sum of the longest dimensions (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or a 50% increase in the LD taking as reference the smallest LD recorded since study entry in the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions, or global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or death due to disease without prior objective documentation of progression." (NCT00025155)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first. Every other cycle, up to 5 years of follow-up

InterventionMonths (Median)
Treatment (Ixabepilone)4.4

[back to top]

Tumor Response

"Percentage of participants with complete and partial tumor response as assessed by the Gynecologic Oncology Group Response Evaluation Criteria in Solid Tumors (GOG RECIST) with one-sided 90% Confidence Interval.~Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), >=30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion, or a 50% decrease in the LD in the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation." (NCT00025155)
Timeframe: Every other cycle until the completion of study treatment with an average of study treatment time as of 3 months.

Interventionpercentage of participants (Number)
Treatment (Ixabepilone)14.3

[back to top]

Number of People With Adverse Effects

(NCT00025155)
Timeframe: Every cycle until completion of study treatment up to 30 days after stopping study treatment

,,,,
InterventionParticipants (Count of Participants)
LeukopeniaThrombocytopeniaNeutropeniaAnemiaHematologicAllergyCardiovascularCoagulationFatigueDermatologicEndocrineGastrointestinalGenitourinary/RenalHemorrhageHepaticInfectionMetabolicNeurologicOcularPainPulmonary
Grade 013391794346454711234810414836433620482937
Grade 1910102301301613115611026120101
Grade 22001213320015130141022314189
Grade 3609430126009101243012
Grade 4101000001001000000010

[back to top]

Duration of Overall Survival

(NCT00045708)
Timeframe: 1.5 years

Interventionmonths (Median)
Group A [Anticonvulsants] Phase 14.9
Group B [No Anticonvulsants] Phase 17.1
Phase 25.8

[back to top] [back to top]

Grade 3 and 4 Toxicity (NCI Common Terminology Criteria for Adverse Events Associated With BMS-247550 Treatment in at Least 5% of Patients

Proportion of patients with serious or life threatening toxicities in at least 5% of patients (NCT00045708)
Timeframe: Up to 30 days post treatment

,,
InterventionParticipants (Count of Participants)
Neutropenia (ANC)WBC (leukopenia)Hypophosphatemia (PO4)Transfusion:pRBCsAnemia (HGB)Hyponatremia
Group A [Anticonvulsants] - Phase 1311000
Group B [No Anticonvulsants] - Phase 1431100
Phase 2442321

[back to top]

Group A (P450) Estimated MTD and Group B (nonP450) Estimated MTD of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma

Starting dose for both Group A and Group B was 5mg/m2/day. A continuing reassessment method (CRM) was employed independently for each group to estimate the maximum tolerated dose. Only toxicity observed during 1st cycle of treatment (21 days) was used for dose finding. Dose limiting toxicity (DLT) defined as: ANC<500/ul, platelets<25,000, febrile neutropenia or treatment-related grade 3 or 4 non-hematologic toxicity with the exception of nausea and vomiting. (NCT00045708)
Timeframe: 21 days (1 cycle)

Interventionmg/m2/day (Number)
Group A [Anticonvulsants]9.6
Group B [No Anticonvulsants]6.8

[back to top] [back to top] [back to top]

Percent of Subjects With 6M Progression Free Survival at the Phase 2 Arm of Study

subjects who are progression free at 6 month scan (NCT00045708)
Timeframe: 6 months

Interventionpercent of patients (Number)
Phase 24

[back to top]

Response Rate of Patients at the MTD

"Complete Response: Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable/improving neurologic exam for min4 wks.~Partial Response: Greater than or equal to 50% reduction in tumor size on volumetric MRI scan, on a stable/decreasing dose of glucocorticoids, with stable/improving neurologic examination for min 4 wks.~Progressive Disease: Progressive neurologic abnormalities not explained by causes unrelated to tumor progression (e.g. anticonvulsant or corticosteroid toxicity, electrolyte abnormalities, hyperglycemia, etc.) or a greater than 25% increase in the volume of the tumor by MRI scan. If neurologic status deteriorates, on stable/increasing dose of steroids, or if new lesions appear on serial MRI, further study treatment will be discontinued.~Stable Disease: A patient whose clinical status and MRI volumetrics do not meet the criteria for Complete Response, Partial Response or Progressive Disease." (NCT00045708)
Timeframe: 3 years

Interventionparticipants (Number)
Phase 20

[back to top]

The Duration of Progression Free Survival (Phase 2)

only patients treated on the nonP450 MTD (NCT00045708)
Timeframe: 1.5 years

Interventionmonths (Median)
Phase 21.5

[back to top]

Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma

Starting dose for both Group A and Group B was 5mg/m2/day. A continuing reassessment method (CRM) was employed independently for each group to estimate the maximum tolerated dose. Only toxicity observed during 1st cycle of treatment (21 days) was used for dose finding. Dose limiting toxicity (DLT) defined as: ANC<500/ul, platelets<25,000, febrile neutropenia or treatment-related grade 3 or 4 non-hematologic toxicity with the exception of nausea and vomiting. (NCT00045708)
Timeframe: 21 days (1 cycle)

,,
InterventionDLTs (Number)
Dose level 5.0mg/m2/dayDose level 6.0mg/m2/dayDose level 6.6mg/m2/dayDose level 6.8mg/m2/dayDose level 7.0mg/m2/dayDose level 7.5mg/m2/dayDose level 7.7mg/m2/dayDose level 8.7mg/m2/dayDose Level 9.5mg/m2/dayDose level 9.6mg/m2/day
Group 3 - MTD (6.8mg/m2/Day) Phase 2NANANA0NANANANANANA
Group A [Anticonvulsants]00NANA0NA0001
Group B [No Anticonvulsants]000121NANANANA

[back to top]

Duration of Response

Duration of response was measured from the time measurement criteria are met for CR(complete response)/CRu(unconfirmed complete response)/PR(partial response), whichever was first recorded, until the first date that PD(progressive disease) was objectively documented. According to the 1999 international response criteria as published by Cheson, CR/CRu is defined as the disappearance of all target lesions; PR is defined as >=50% decrease in the sum of the products of the greatest diameters; PD is defined as >=50% increase from nadir in the sum of the products of the greatest diameters of any previously identified abnormal node for PRs or nonresponders, or appearance of any new lesion during or at the end of therapy. (NCT00058019)
Timeframe: up to 3 years

InterventionDays (Median)
Cohort 1 (Chemosensitive)291

[back to top]

Objective Overall Response Rate

The 1999 international response criteria (http://www.ncbi.nlm.nih.gov/pubmed/10561185) as published by Cheson was used for the definition of target lesions and CT scans were used for response assessment. CR(complete response)/CRu(unconfirmed complete response) requires disappearance of all target lesions; PR (partial response) requires >=50% decrease in the sum of the products of the greatest diameters; Overall Response (OR)=CR/CRu+PR. (NCT00058019)
Timeframe: up to 3 years

Interventionparticipants (Number)
Cohort 1 (Chemosensitive)14
Cohort 2 (Chmoresistant)0

[back to top]

Overall Survival

Defined as the time from the first day of therapy to the date of death. If the patient was lost to follow-up, survival was censored on the last date the patient was known to be alive. (NCT00058019)
Timeframe: up to 3 years

InterventionDays (Median)
Cohort 1 (Chemosensitive)501
Cohort 2 (Chmoresistant)98

[back to top]

Safety and Toxicity of Ixabepilone

Number of patients experiencing adverse event grade 3 or above. Grade was determined by the National Cancer Institute Common Toxicity Criteria (CTC) version 2.0. Adverse events possibly, probably, or definitely attributed to use of ixabepilone. (NCT00058019)
Timeframe: up to 3 years

Interventionparticipants (Number)
Cohort 1 (Chemosensitive)27
Cohort 2 (Chmoresistant)8

[back to top]

Time to Progression

Defined as the time from the first day of treatment until the date PD(progressive disease) or death is first reported. Patients who died without a reported prior progression was considered to have progressed on the day of their death. Patients who did not progress was censored at the day of their last tumor assessment. According to the 1999 international response criteria as published by Cheson, progression/progressive disease is defined as >=50% increase from nadir in the sum of the products of the greatest diameters of any previously identified abnormal node for PRs or nonresponders, or appearance of any new lesion during or at the end of therapy. (NCT00058019)
Timeframe: up to 3 years

InterventionDays (Median)
Cohort 1 (Chemosensitive)112
Cohort 2 (Chmoresistant)84

[back to top]

Kaplan-Meier Estimate of Overall Survival at 3 Years for HER2+ Patients

Survival estimate from the Kaplan-Meier curve of the proportion of patients alive at 3 years. (NCT00077376)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years

InterventionPercentage of Participants (Number)
Trastuzumab/Ixabepilone/Carboplatin50

[back to top]

Time to Disease Progression for All Treated Patients

This interval will be measured from the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression based on RECIST. Patients progression-free at last follow-up were censored. (NCT00077376)
Timeframe: Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years

InterventionMonths (Median)
Trastuzumab/Ixabepilone/Carboplatin8.2

[back to top]

Time to Disease Progression for HER2+ Patients

This interval will be measured from the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression based on RECIST. Patients progression-free at last follow-up were censored. (NCT00077376)
Timeframe: Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years

InterventionMonths (Median)
Trastuzumab/Ixabepilone/Carboplatin7.1

[back to top]

Time to Treatment Failure for All Treated Patients

Time from study entry to the date at which a patient was removed from treatment due to progression, toxicity, refusal or death. If a patient was considered to be a major treatment violation or was taken off study as a non-protocol failure, the patient would be censored on the date he/she was removed from treatment. (NCT00077376)
Timeframe: Assessed every cycle until treatment discontinuation

InterventionMonths (Median)
Trastuzumab/Ixabepilone/Carboplatin5.9

[back to top]

Objective Response for All Treated Patients (the Best Response a Patient Has Ever Experienced on Study)

"To assess objective response, it is necessary to estimate the overall tumor burden at baseline to which subsequent measurements will be compared. The same method of assessment and the same technique should be used to characterize each lesion at baseline and during follow-up.~The best overall response based on RECIST is the best response recorded from registration until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since registration. The best response was determined based on the tumor responses in target and nontarget lesions, with or without new lesions. To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. To be assigned a status of stable disease, measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks." (NCT00077376)
Timeframe: Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years

InterventionParticipants (Number)
Compelete ResponsePartial ResponseNo Change/ StableProgressionUnevaluable
Trastuzumab/Ixabepilone/Carboplatin42215162

[back to top]

Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study)

"To assess objective response, it is necessary to estimate the overall tumor burden at baseline to which subsequent measurements will be compared. The same method of assessment and the same technique should be used to characterize each lesion at baseline and during follow-up.~The best overall response based on RECIST is the best response recorded from registration until disease progression/recurrence, taking as reference for progressive disease the smallest measurements recorded since registration. The best response was determined based on the tumor responses in target and nontarget lesions, with or without new lesions. To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. To be assigned a status of stable disease, measurements must have met the stable disease criteria at least once after study entry at a minimum interval of 8 weeks." (NCT00077376)
Timeframe: Assessed every 3 cycles during induction therapy and every 6 cycles during maintenance therapy until disease progression or up to 5 years

InterventionParticipants (Number)
Complete ResponsePartial ResponseNo Change/ StableProgressionUnevaluable
Trastuzumab/Ixabepilone/Carboplatin31310112

[back to top]

Time to Treatment Failure for HER2+ Patients

Time from study entry to the date at which a patient was removed from treatment due to progression, toxicity, refusal or death. If a patient was considered to be a major treatment violation or was taken off study as a non-protocol failure, the patient would be censored on the date he/she was removed from treatment. (NCT00077376)
Timeframe: Assessed every cycle until treatment discontinuation

InterventionMonths (Median)
Trastuzumab/Ixabepilone/Carboplatin5.4

[back to top]

Kaplan-Meier Estimate of Overall Survival at 3 Years for All Treated Patients

Survival estimate from the Kaplan-Meier curve of the proportion of patients alive at 3 years. (NCT00077376)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 years

InterventionPercentage of Participants (Number)
Trastuzumab/Ixabepilone/Carboplatin48

[back to top]

Time to Treatment Failure (TTF)

Time to Treatment Failure as determined by RECIST v.1.0 Criteria: is the time from the date of randomization or start of treatment to the earliest date of progression, date of death due to any cause, or date of discontinuation due to reasons of adverse events, abnormal laboratory values, abnormal test procedure results, subject withdraws consent, or date 'Lost to follow up'. (NCT00079326)
Timeframe: up to 6 years

Interventionmonths (Median)
Cohort 1: No Prior Chemo or Trastuzumab Treatment6.6
Cohort 2: 1-2 Prior Trastuzumab Treatment Regimens6.2

[back to top]

Overall Response Rate

Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by computed tomography or magnetic resonance imaging scans: Complete response (CR) is defined as the disappearance of all target lesions; Partial Response is defined by at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = CR + PR. (NCT00079326)
Timeframe: Up to 6 years

Interventionpercentage of participants (Number)
Cohort 1: No Prior Chemo or Trastuzumab Treatment73
Cohort 2: 1-2 Prior Trastuzumab Treatment Regimens25

[back to top]

Duration of Measurable Disease Response

Duration of measurable disease response was defined as the time from the date when measurement criteria were met for complete or partial response, whichever status was recorded first, until the first date that recurrent or progressive disease was objectively documented based on RECIST (Response Evaluation Criteria in Solid Tumors). Only patients with measurable disease response were included in this analysis. (NCT00087139)
Timeframe: Every 8 weeks during treatment; then every 3 months if <2 years from study entry; then every 6 months if 2-5 years from study entry

InterventionMonths (Median)
Ixabepilone - no Prior Chemo5.1
Ixabepilone - Prior Taxane3.7

[back to top]

Duration of PSA Response

Duration of PSA response was defined as the time from the date of onset of PSA response until the date the criteria were met for PSA progression. Only patients with a PSA response were included in this analysis. The results were reported separately for 3 strata. (NCT00087139)
Timeframe: Every 4 weeks during treatment; then every 3 months if <2 years from study entry; then every 6 months if 2-5 years from study entry

InterventionMonths (Median)
Ixabepilone - no Prior Chemo6.0
Ixabepilone - Prior Taxane7.6
Ixabepilone - Two Prior ChemoNA

[back to top]

Proportion of Patients With Measurable Disease Response (Best Overall Response)

"Only patients with measurable disease were included in this analysis. The proportion of patients with measurable disease response (based on RECIST: Response Evaluation Criteria in Solid Tumors) was reported separately for 3 strata.~Per RECIST criteria, Complete response (CR)= disappearance of all target and nontarget lesions Partial response (PR)= >=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.~Objective response = CR + PR" (NCT00087139)
Timeframe: Every 8 weeks during treatment; then every 3 months if <2 years from study entry; then every 6 months if 2-5 years from study entry

Interventionproportion of participants (Number)
Ixabepilone - no Prior Chemo0.23
Ixabepilone - Prior Taxane0.08
Ixabepilone - Two Prior Chemo0

[back to top]

Proportion of Patients With PSA Response

PSA response is defined as a decline from baseline value by >=50%, or normalization of PSA (PSA < 0.2 ng/lm), confirmed by a second measurement >= 4 weeks later. The proportion of patients with PSA response was reported separately for 3 strata. Additional patients accrued to this study were not included in this analysis. (NCT00087139)
Timeframe: Every 4 weeks during treatment; then every 3 months if <2 years from study entry; then every 6 months if 2-5 years from study entry

InterventionProportion of participants (Number)
Ixabepilone - no Prior Chemo0.33
Ixabepilone - Prior Taxane0.24
Ixabepilone - Two Prior Chemo0.18

[back to top]

Tumor Response

RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate. (NCT00095979)
Timeframe: Every other cycle for first 6 months; then every six months thereafter until completion of study treatment; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease

Interventionpercentage of participants (Number)
Ixabepilone12

[back to top]

Overall Survival

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT00095979)
Timeframe: From study entry to death or last contact, up to 5 years of follow-up.

Interventionmonths (Median)
Ixabepilone8.8

[back to top]

Frequency and Severity of Observed Adverse Effects Associated With Protocol Therapy (CTCAE Version 3)

(NCT00095979)
Timeframe: Every cycle until completion of study treatment up to 30 days after stopping study treatment (average length of data collection = 4 months)

,,,,
InterventionParticipants (Count of Participants)
LeukopeniaNeutropeniaAnemiaThrombocytopeniaAllergy/ImmunologyAuditory/earCardiacCoagulationConstitutionalDermatologicGastrointestinalGenitourinaryHemorrhageInfectionLymphaticsMetabolicMusculoskeletalNeurosensoryOther neurologicOcular/visualPainPulmonaryAlopeciaVascular
Grade 1951213401015711110893194391070
Grade 2147294020014211511228473384231
Grade 3171461002192120280304403200
Grade 47121100001000000100100001
Grade 5000000000000000000000100

[back to top]

Progression-free Survival

Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions. (NCT00095979)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.

Interventionmonths (Median)
Ixabepilone3.1

[back to top]

Number of Participants With Best Overall Response-Phase I

This was defined as the number of participants whose best overall response was CR or PR by RECIST. Per RECIST: CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a >=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria. (NCT00171834)
Timeframe: Best achieved overall response according to RECIST from start of study until study discontinuation. Imaging was assessed every second cycle (ie. approximately every 6 weeks) until disease progression or discontinuation. Average 18 weeks

,,,,
InterventionParticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)UnknownBest overall response (CR,PR) & the response rate
Patupilone ≤7.0 mg/m^2 (Phase I)001500
Patupilone 10.0-11.5 mg/m^2 (Phase I)014611
Patupilone 12.0-13.0 mg/m^2 (Phase I)005120
Patupilone 7.5-8.0 mg/m^2 (Phase I)032433
Patupilone 8.5-9.5 mg/m^2 (Phase I)015511

[back to top]

Time to Progression (TTP)-Phase I and Phase II

Time to progression was measured from the start of study drug to the date of first documented disease progression by RECIST, discontinuation due to disease progression, or death from underlying cancer, whichever event occurred first. If a patient had not progressed by RECIST, discontinued due to disease progression, or died from underlying cancer, TTP was censored at the time of last adequate tumor assessment. However, if a patient took any new cancer therapy prior to PD or death, then TTP was censored at the date of last adequate tumor assessment prior to the start date of new cancer therapy. (NCT00171834)
Timeframe: From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks

InterventionMonths (Median)
Patupilone (EPO906) Phase I2.1
Patupilone (EPO906) Phase II2.1

[back to top]

Time to Overall Response -Phase I and Phase II

Time to overall response (CR or PR) measured by RECIST was the time between study start until date of first documented response (CR or PR). (NCT00171834)
Timeframe: From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Average 18 weeks

InterventionMonths (Median)
Patupilone (EPO906) Phase I2.6
Patupilone (EPO906) Phase II3.4

[back to top]

Overall Survival Time-Phase I and Phase II

Overall survival (OS) time was measured from the start of study drug to the date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact. Data was collected post treatment every 3 months until approximately 70% of patients have reached the survival endpoint (Phase I + Phase II). (NCT00171834)
Timeframe: From start of study drug to date of death due to any cause. Follow-up after treatment discontinuation approximately every 3 months until approximately 70% of participants have reached the survival endpoint. Average 9.75 months

InterventionMonths (Median)
Patupilone (EPO906) Phase I9.2
Patupilone (EPO906) Phase II10.3

[back to top]

Duration of Stable Disease-Phase I and Phase II

Duration of stable disease (CR, PR, or SD) by RECIST was defined as the time from start of study drug to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first. (NCT00171834)
Timeframe: Imaging was assessed every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from treatment . Average 18 weeks

InterventionMonths (Median)
Patupilone (EPO906) Phase I3.7
Patupilone (EPO906) Phase II5.6

[back to top]

Phase II: Number of Participants With Best Overall Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST)

Overall response is the number of participants who had a complete response (CR) or a partial response (PR) based on local investigator's assessment of RECIST criteria. Per RECIST: CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions; Progressive disease (PD), a >=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; Stable Disease (SD), small changes that do not meet previously given criteria. (NCT00171834)
Timeframe: At baseline, then every second cycle (approximately every 6 weeks), until disease progression or discontinuation. Average 18 weeks.

InterventionParticipants (Number)
Complete ResponsePartial Response (PR)Stable Disease (SD)Progressive Disease (PD)UnknownBest overall response (CR, PR) & the response rate
Patupilone 10 mg/m^2 (Phase II) NSCLC Cohort0691376

[back to top]

Phase I: Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)

The MTD was defined as the highest dose of patupilone administered every three weeks (q3w) where not more than one out of six patients experienced a DLT using a standard 3+3 design. Dose escalation started at 6.5 mg/m^2 until MTD in steps of 0.5 mg/m^2 until 12 mg/m^2, then in steps of 1 mg/m^2 till 13.0 mg/m^2. DLTs were assessed during cycle 1. During this time frame, no more than one DLT occurred in any of the explored dose levels up to 13 mg/m^2, thus, the MTD as defined by the protocol was not reached in this study. (NCT00171834)
Timeframe: Cycle 1 (21 days)

,,,,,,,,,,,,
InterventionDose Limiting Toxicity (DLT) (Number)
AstheniaDiarrheaAny DLT
Patupilone 10.0 mg/m^2 (Phase I)000
Patupilone 10.5 mg/m^2 (Phase I)000
Patupilone 11.0 mg/m^2 (Phase I)000
Patupilone 11.5 mg/m^2 (Phase I)000
Patupilone 12.0 mg/m^2 (Phase I)000
Patupilone 13.0 mg/m^2 (Phase I)011
Patupilone 6.5 mg/m^2 (Phase I)000
Patupilone 7.0 mg/m^2 (Phase I)000
Patupilone 7.5 mg/m^2 (Phase I)101
Patupilone 8.0 mg/m^2 (Phase I)011
Patupilone 8.5 mg/m^2 (Phase I)011
Patupilone 9.0 mg/m^2 (Phase I)000
Patupilone 9.5 mg/m^2 (Phase I)000

[back to top]

Duration of Overall Response -Phase I and Phase II

Duration of overall response (CR or PR) measured by RECIST was measured from the first documented CR or PR to the date of first documented disease progression or discontinuation due to disease progression, or death from underlying cancer, whichever event occured first. (NCT00171834)
Timeframe: Duration of response according to RECIST from start of study until study discontinuation. Duration of response was assessed every second cycle ( i.e. approximately every 6 weeks) until disease progression or discontinuation from study. Average 18 weeks

InterventionMonths (Median)
Patupilone (EPO906) Phase I2.6
Patupilone (EPO906) Phase IINA

[back to top]

Maximum Tolerated Dose

The phase I component of the study included 30 patients with breast and ovarian cancer. A protocol amendment was made during phase I trial from a treatment regimen of Schedule A (ixabepilone every 3-4 weeks) to Schedule B (ixabepilone every week). The maximum tolerated dose was determined to be the preceding dose of any dose that resulted in 2 DLT events. Schedule B was carried forward to the phase II trial. The Maximum Tolerated Dose for Schedule B is reported. Please see (Chuang et al., 2010) for additional details (NCT00182767)
Timeframe: Once 2 DLT events occur in patients during the first 28 days of treatment (cycle 1), the preceding dose will be designated the maximum tolerated dose (MTD).

Interventionmg/m2 (Number)
Treatment (Ixabepilone and Doxorubicin)16

[back to top]

Proportion of Patients Responding to Therapy (Complete Response [CR], Partial Response [PR], or Stable Disease [SD]), Assessed According to Response Evaluation Criteria in Solid Tumors (RECIST) and Cancer Antigen-125 (CA-125) Response Criteria (Phase II)

(NCT00182767)
Timeframe: Up to 2 years

Interventionparticipants (Number)
Ovarian CancerBreast Cancer
Treatment (Ixabepilone and Doxorubicin)207

[back to top]

Progression-free Survival

We will summarize progression-free survival by Kaplan-Meier survival analysis. (NCT00182767)
Timeframe: The time from start of treatment to time of progression or death, assessed up to 2 years

Interventionmonths (Median)
Treatment (Ixabepilone and Doxorubicin)4.1

[back to top]

Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I)

Dose-Limiting Toxicities are assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events classification and usually encompasses all grade 3 or higher toxicities (NCT00182767)
Timeframe: 28 days

Interventionparticipants (Number)
Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 11
Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 21
Ixabepilone 40mg/m2 and Doxorubicin 30mg/m2: Level 32
Ixabepilone 13mg/m2 and Doxorubicin 30mg/m2: Level 40
Ixabepilone 16mg/m2 and Doxorubicin 30mg/m2: Level 50

[back to top]

Time to Progression (Phase II)

Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death

Interventionmonths (Median)
Treatment (Combination Chemotherapy)4.4

[back to top]

Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).

Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)

InterventionParticipants (Count of Participants)
Phase I Group I0
Phase Group II0
Phase I Group III0
Phase I Group IV1
Phase I Group V2
Phase I Group VI2
Phase I Group Va0
Phase I Group VIa1

[back to top]

Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)

"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death

InterventionParticipants (Count of Participants)
Treatment (Combination Chemotherapy)25

[back to top]

Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)

This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death

InterventionAdverse Events (above threshold) (Number)
Phase I Treatment (Groups I-VIa)62

[back to top]

Overall Survival

Median time (months) that patients survived during the duration of the study. (NCT00450866)
Timeframe: 48 months from start of study

Interventionmonths (Median)
Epothilone B (Groups A and B)12.7

[back to top]

Toxicity as Measured by NCI CTCAE v3.0

Percent of patients that experience the most common grade 3 and above toxicities possibly related to study drug - to be measured using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. (NCT00450866)
Timeframe: 3 months after treatment

Interventionpercentage of participants (Number)
Epothilone B (Groups A and B)44

[back to top]

CNS Response Rate, for Measurable Disease Will be Assessed by the Modified McDonald Criteria

Complete Response (CR): the circumstance when the tumor is no longer seen by neuroimaging Partial Response (PR): Decrease of >50% in the product of two diameters Stable Disease (SD): the circumstance when the scan shows no change. Progression (P): a > 25% increase in tumor area (two diameters) (NCT00450866)
Timeframe: 3 months after treatment

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progression (P)
Epothilone B: Group A05931
Epothilone B: Group B0028

[back to top]

Systemic Disease Response Rate for Measurable Disease Will be Assessed by the Modified McDonald Criteria

Complete Response (CR): the circumstance when the tumor is no longer seen by neuroimaging Partial Response (PR): Decrease of >50% in the product of two diameters Stable Disease (SD): the circumstance when the scan shows no change. Progression (P): a > 25% increase in tumor area (two diameters) (NCT00450866)
Timeframe: 3 months after treatment

Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)Progression (P)
Epothilone B (Groups A and B)171829

[back to top]

Central Nervous System (CNS) Progression-free Survival(PFS)

"The number of patients that are documented to have progression free survival at 3 months after treatment. Progression free is define as <25% increase in tumor area.~PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death." (NCT00450866)
Timeframe: 3 months after treatment

Interventionparticipants (Number)
Epothilone B: Group A12
Epothilone B: Group B2

[back to top]

Time to Treatment Failure

Time from registration until treatment failure, defined as early termination of protocol therapy for any reason, first disease progression or death without progression. Surviving participants who were failure free were censored as date last known alive and failure free. Distribution was estimated using the Kaplan Meier product-limit method. (NCT00785291)
Timeframe: Time from randomization until progression, death, or yearly termination of protocol therapy (up to 5 years)

Interventionmonths (Median)
Arm A (Paclitaxel)6.6
Arm B (Nab-paclitaxel)5.19
Arm C (Ixabepilone)4.93

[back to top]

Progression Free Survival

Progression-free survival (PFS) is defined as the interval from registration until first disease progression, regardless of site, or death resulting from any cause, which ever occurred first. Distribution was estimated using the Kaplan Meier product-limit method. Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per Response Evaluation Criteria in Solid Tumors [RECIST] criteria). (NCT00785291)
Timeframe: Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)

Interventionmonths (Median)
Arm A (Paclitaxel)10.97
Arm B (Nab-paclitaxel)9.3
Arm C (Ixabepilone)7.36

[back to top]

Overall Survival

Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method. (NCT00785291)
Timeframe: Time from randomization to death or last follow-up (up to 5 years)

Interventionmonths (Median)
Arm A (Paclitaxel)26.55
Arm B (Nab-paclitaxel)23.52
Arm C (Ixabepilone)23.53

[back to top]

Objective Tumor Response Rate

Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a Complete Response (disappearance of all target lesions) or Partial Response (30% decrease in sum of longest diameter of target lesions). (NCT00785291)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
Arm A (Paclitaxel)38.2
Arm B (Nab-paclitaxel)34.1
Arm C (Ixabepilone)25.6

[back to top]

12 Month Progression Free Survival

Percentage of participants who were alive and progression free at 12 months. The 12 month progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00785291)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Arm A (Paclitaxel)45
Arm B (Nab-paclitaxel)36
Arm C (Ixabepilone)28

[back to top]

Frequency and Severity of Toxicity as Assessed by CTCAE v3.0 for Each of the Three Arms.

(NCT00977574)
Timeframe: Median of 10 cycles of treatment plus 30 days

,,
InterventionParticipants (Count of Participants)
Any Adverse Event, Any GradeAny Adverse Event, Grades >= 3Any Adverse Event, Grade 5
Arm I (Paclitaxel, Carboplatin, Bevacizumab)1121054
Arm II (Paclitaxel, Carboplatin, Temsirolimus)1131116
Arm III (Ixabepilone, Carboplatin, Bevacizumab)1141096

[back to top]

The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.

RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required. (NCT00977574)
Timeframe: Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months

InterventionParticipants (Count of Participants)
Arm I (Paclitaxel, Carboplatin, Bevacizumab)53
Arm II (Paclitaxel, Carboplatin, Temsirolimus)47
Arm III (Ixabepilone, Carboplatin, Bevacizumab)45

[back to top]

Number of Participants Who Progressed or Died by 25 Months From Enrollment

PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574 (NCT00977574)
Timeframe: at 25 months

InterventionParticipants (Count of Participants)
Arm I (Paclitaxel, Carboplatin, Bevacizumab)86
Arm II (Paclitaxel, Carboplatin, Temsirolimus)96
Arm III (Ixabepilone, Carboplatin, Bevacizumab)88

[back to top]

The Median Duration of Overall Survival for Each of the Three Arms.

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT00977574)
Timeframe: Time from date of study entry to time of death or the date of last contact, assessed up to 5 years

Interventionmonths (Median)
Arm I (Paclitaxel, Carboplatin, Bevacizumab)34
Arm II (Paclitaxel, Carboplatin, Temsirolimus)25
Arm III (Ixabepilone, Carboplatin, Bevacizumab)25.2

[back to top]

Objective Tumor Response

Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response as assessed by RECIST 1.1. (NCT01168232)
Timeframe: Every other cycle for first 6 months; then every 3 months thereafter until completion of study treatment; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.1 cycle is 21 days

Interventionpercentage (Number)
Ixabepilone11.8

[back to top]

Overall Survival

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT01168232)
Timeframe: From study entry to death or last contact, up to 5 years of follow-up.

Interventionmonths (Median)
Ixabepilone7.7

[back to top]

Adverse Events (Grade 3 or Higher) During Treatment Period.

Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0 (NCT01168232)
Timeframe: During treatment and up to 30 days after stopping the study treatment

Interventionparticipants (Number)
LeukopeniaThrombocytopeniaNeutropeniaAnemiaOther InvestigationsOther Blood/lymphaticsCardiac DisordersGastrointestinal disordersGeneral disorders and administration site conditioInfections and infestationsMetabolism and nutrition disordersMusculoskelatal and connective tissue disordersNeoplasms benign, malignant and unspecifiedPeripheral sensory neuropathyOther nervous system disordersRespitory, thoracic and mediastinal disordersVascular disorders
Ixabepilone15016542169312121258

[back to top]

Progression-free Survival

Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1 (NCT01168232)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.

Interventionmonths (Median)
Ixabepilone1.7

[back to top]